Skip to main content Back to Top
Advertisement

2/21/2020

Nicardipine Hydrochloride Injection

Products Affected - Description

    • Cardene injection, Baxter, 20 mg/200 mL in 0.9% sodium chloride, premixed bag, 10 count, NDC 10122-0313-10
    • Cardene injection, Baxter, 40 mg/200 mL in 0.9% sodium chloride, premixed bag, NDC 10122-0325-10

Reason for the Shortage

    • Baxter recently acquired Cardene from Chiesi. They have Cardene on shortage due to manufacturing delays. They are not marketing Cardene 20 mg/200 mL in 5% dextrose premixed bags.
    • Hikma did not provide a reason for the shortage.
    • Mylan discontinued nicardipine vials.
    • Sun Pharma discontinued nicardipine ampules.
    • Chiesi discontinued Cardene 40 mg/200 mL in 5% dextrose premixed bags in mid-2019.

Available Products

    • Nicardipine Hydrochloride injection, Hikma, 2.5 mg/mL, 10 mL vial, 10 count, NDC 00143-9689-10

Estimated Resupply Dates

    • Baxter has Cardene IV 40 mg/200 mL and 20 mg/200 mL in 0.9% sodium chloride premixed bags on back order and the company estimates a release date of late-February 2020.

Updated

Updated February 21, 2020 by Michelle Wheeler, PharmD, Drug Information Specialist. Created June 13, 2019 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2020, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.